BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng LY, Yang J, Liu S. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert Opin Investig Drugs 2017;26:63-73. [PMID: 27918208 DOI: 10.1080/13543784.2017.1269170] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Chen Z, Cui Q, Caffrey M, Rong L, Du R. Small Molecule Inhibitors of Influenza Virus Entry. Pharmaceuticals (Basel) 2021;14:587. [PMID: 34207368 DOI: 10.3390/ph14060587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhang Y, Xu C, Zhang H, Liu GD, Xue C, Cao Y. Targeting Hemagglutinin: Approaches for Broad Protection against the Influenza A Virus. Viruses 2019;11:E405. [PMID: 31052339 DOI: 10.3390/v11050405] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
3 Kim JI, Lee S, Lee GY, Park S, Bae JY, Heo J, Kim HY, Woo SH, Lee HU, Ahn CA, Bang HJ, Ju HS, Ok K, Byun Y, Cho DJ, Shin JS, Kim DY, Park MS, Park MS. Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses. J Virol 2019;93:e00878-19. [PMID: 31167918 DOI: 10.1128/JVI.00878-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
4 Yang J, Huang Y, Liu S. Investigational antiviral therapies for the treatment of influenza. Expert Opin Investig Drugs 2019;28:481-8. [PMID: 31018720 DOI: 10.1080/13543784.2019.1606210] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
5 Zhao MZ, Guo X, Sun B, Sun XF, Pang GF, Yang LY, Zhao X, Sun LX, Zhang Q. HA of H1N1 enhanced the expression of ICAM-1 and IL-6 in HUVECs and pathological injury in the lungs in mice. Gene 2021;801:145854. [PMID: 34274468 DOI: 10.1016/j.gene.2021.145854] [Reference Citation Analysis]
6 Scala MC, Sala M, Pietrantoni A, Spensiero A, Di Micco S, Agamennone M, Bertamino A, Novellino E, Bifulco G, Gomez-Monterrey IM, Superti F, Campiglia P. Lactoferrin-derived Peptides Active towards Influenza: Identification of Three Potent Tetrapeptide Inhibitors. Sci Rep 2017;7:10593. [PMID: 28878220 DOI: 10.1038/s41598-017-10492-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
7 Zabrodskaya YA, Lebedev DV, Egorova MA, Shaldzhyan AA, Shvetsov AV, Kuklin AI, Vinogradova DS, Klopov NV, Matusevich OV, Cheremnykh TA, Dattani R, Egorov VV. The amyloidogenicity of the influenza virus PB1-derived peptide sheds light on its antiviral activity. Biophys Chem 2018;234:16-23. [PMID: 29328990 DOI: 10.1016/j.bpc.2018.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
8 Pshenichnaya NY, Bulgakova VA, Lvov NI, Poromov AA, Selkova EP, Grekova AI, Shestakova IV, Maleev VV, Leneva IA. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Ter Arkh 2019;91:56-63. [PMID: 31094461 DOI: 10.26442/00403660.2019.03.000127] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
9 Zhou X, Zhao M, Liu Y, Chen Q, Shen L. Statistical Binding Matching between Influenza A Virus and Dynamic Glycan Clusters Determines Its Adhesion onto Lipid Membranes. Langmuir 2020;36:15212-9. [PMID: 33307709 DOI: 10.1021/acs.langmuir.0c02047] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Chen F, Liu T, Xu J, Huang Y, Liu S, Yang J. Key amino acid residues of neuraminidase involved in influenza A virus entry. Pathog Dis 2019;77:ftz063. [PMID: 31702775 DOI: 10.1093/femspd/ftz063] [Reference Citation Analysis]
11 Ding Y, Chen L, Wu W, Yang J, Yang Z, Liu S. Andrographolide inhibits influenza A virus-induced inflammation in a murine model through NF-κB and JAK-STAT signaling pathway. Microbes Infect 2017;19:605-15. [PMID: 28889969 DOI: 10.1016/j.micinf.2017.08.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
12 Sriwilaijaroen N, Suzuki Y. Hemagglutinin Inhibitors are Potential Future Anti-Influenza Drugs for Mono- and Combination Therapies. In: Hirabayashi J, editor. Lectin Purification and Analysis. New York: Springer US; 2020. pp. 547-65. [DOI: 10.1007/978-1-0716-0430-4_48] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Sette-DE-Souza PH, Costa MJF, Araújo FAC, Alencar EN, Amaral-Machado L. Two phytocompounds from Schinopsis brasiliensis show promising antiviral activity with multiples targets in Influenza A virus. An Acad Bras Cienc 2021;93:e20210964. [PMID: 34817041 DOI: 10.1590/0001-3765202120210964] [Reference Citation Analysis]
14 Lu W, Pieters RJ. Carbohydrate–protein interactions and multivalency: implications for the inhibition of influenza A virus infections. Expert Opinion on Drug Discovery 2019;14:387-95. [DOI: 10.1080/17460441.2019.1573813] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
15 Chen X, Liu S, Goraya MU, Maarouf M, Huang S, Chen JL. Host Immune Response to Influenza A Virus Infection. Front Immunol 2018;9:320. [PMID: 29556226 DOI: 10.3389/fimmu.2018.00320] [Cited by in Crossref: 130] [Cited by in F6Publishing: 119] [Article Influence: 32.5] [Reference Citation Analysis]
16 Pandey A, Nikam AN, Shreya AB, Mutalik SP, Gopalan D, Kulkarni S, Padya BS, Fernandes G, Mutalik S, Prassl R. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sci 2020;256:117883. [PMID: 32497632 DOI: 10.1016/j.lfs.2020.117883] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 25.0] [Reference Citation Analysis]
17 Han L, Chen C, Han X, Lin S, Ao X, Han X, Wang J, Ye H. Structural Insights for Anti-Influenza Vaccine Design. Comput Struct Biotechnol J 2019;17:475-83. [PMID: 31007873 DOI: 10.1016/j.csbj.2019.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jeyaram RA, Radha CA, Gromiha MM, Veluraja K. Design of fluorinated sialic acid analog inhibitor to H5 hemagglutinin of H5N1 influenza virus through molecular dynamics simulation study. J Biomol Struct Dyn 2020;38:3504-13. [PMID: 31594458 DOI: 10.1080/07391102.2019.1677500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Elshabrawy HA. SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. Vaccines (Basel) 2020;8:E335. [PMID: 32585913 DOI: 10.3390/vaccines8020335] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
20 Hong EH, Song JH, Kim SR, Cho J, Jeong B, Yang H, Jeong JH, Ahn JH, Jeong H, Kim SE, Chang SY, Ko HJ. Morin Hydrate Inhibits Influenza Virus entry into Host Cells and Has Anti-inflammatory Effect in Influenza-infected Mice. Immune Netw 2020;20:e32. [PMID: 32895619 DOI: 10.4110/in.2020.20.e32] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Zhang Q, Liang T, Nandakumar KS, Liu S. Emerging and state of the art hemagglutinin-targeted influenza virus inhibitors. Expert Opin Pharmacother 2021;22:715-28. [PMID: 33327812 DOI: 10.1080/14656566.2020.1856814] [Reference Citation Analysis]
22 Ustinov NB, Zavyalova EG, Smirnova IG, Kopylov AM. The Power and Limitations of Influenza Virus Hemagglutinin Assays. Biochemistry (Mosc) 2017;82:1234-48. [PMID: 29223151 DOI: 10.1134/S0006297917110025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
23 Zhang Y, Xu Z, Cao Y. Host-Virus Interaction: How Host Cells Defend against Influenza A Virus Infection. Viruses 2020;12:E376. [PMID: 32235330 DOI: 10.3390/v12040376] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
24 Du R, Cheng H, Cui Q, Peet NP, Gaisina IN, Rong L. Identification of a novel inhibitor targeting influenza A virus group 2 hemagglutinins. Antiviral Res 2021;186:105013. [PMID: 33428962 DOI: 10.1016/j.antiviral.2021.105013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019;167:45-67. [PMID: 30974127 DOI: 10.1016/j.antiviral.2019.04.006] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 26.3] [Reference Citation Analysis]
26 Chen ZR, Zhou Y, Liu J, Peng HW, Zhou J, Zhong HL, Liu LL, Lai MF, Wei XH, Wen JH. Pharmacotherapics Advice in Guidelines for COVID-19. Front Pharmacol. 2020;11:950. [PMID: 32670066 DOI: 10.3389/fphar.2020.00950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Cheng HW, Wang HW, Wong TY, Yeh HW, Chen YC, Liu DZ, Liang PH. Synthesis of S-linked NeuAc-α(2-6)-di-LacNAc bearing liposomes for H1N1 influenza virus inhibition assays. Bioorg Med Chem 2018;26:2262-70. [PMID: 29472127 DOI: 10.1016/j.bmc.2018.02.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
28 Li H, Li M, Xu R, Wang S, Zhang Y, Zhang L, Zhou D, Xiao S. Synthesis, structure activity relationship and in vitro anti-influenza virus activity of novel polyphenol-pentacyclic triterpene conjugates. European Journal of Medicinal Chemistry 2019;163:560-8. [DOI: 10.1016/j.ejmech.2018.12.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
29 Szűcs Z, Kelemen V, Le Thai S, Csávás M, Rőth E, Batta G, Stevaert A, Vanderlinden E, Naesens L, Herczegh P, Borbás A. Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents. Eur J Med Chem 2018;157:1017-30. [PMID: 30170320 DOI: 10.1016/j.ejmech.2018.08.058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Su X, Wang Q, Wen Y, Jiang S, Lu L. Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells. Front Microbiol 2020;11:1063. [PMID: 32523582 DOI: 10.3389/fmicb.2020.01063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
31 Al-Horani RA, Kar S, Aliter KF. Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. Int J Mol Sci 2020;21:E5224. [PMID: 32718020 DOI: 10.3390/ijms21155224] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
32 Wang L, Xu X, Ruan J, Lin S, Jiang J, Ye H. Quadruple therapy for asymptomatic COVID-19 infection patients. Expert Rev Anti Infect Ther 2020;18:617-24. [PMID: 32362193 DOI: 10.1080/14787210.2020.1758066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
33 Sadeghsoltani F, Mohammadzadeh I, Safari MM, Hassanpour P, Izadpanah M, Qujeq D, Moein S, Vaghari-Tabari M. Zinc and Respiratory Viral Infections: Important Trace Element in Anti-viral Response and Immune Regulation. Biol Trace Elem Res 2021. [PMID: 34368933 DOI: 10.1007/s12011-021-02859-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]